PharmEnable
pharmenabletx.com
Actively hiring
Drug Discovery
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$7.5M
1 round on record
Latest round
$7.5M
Venture round · May 2023 · 3 yr ago
Backers
1
Parkwalk Advisors
The money's age
Long since its last round
40 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
May 19, 2023
Raised a round Venture round $7.5M · led by MP Healthcare
Jul 14, 2021
Partnership PharmEnable and LifeArc partner to discover novel oral antiviral drugs to treat coronaviruses · pharmenabletx.com
2018
Founded
Tractionpublic signals, read monthly
Web presence
top 8%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | May 2023 | $7.5M | MP Healthcare lead | pharmenabletx.com |
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
backs Valo Health, CIMPLRX
backs Enveda Biosciences
Similar startupsby what they do, their industry and backers
Regor combines a cutting-edge drug discovery engine with target validation and optimization for preclinical candidates in metabolism…
Enveda Biosciences is a drug discovery company founded in 2019 that searches the chemistry of plants and other organisms for new medicines…
Avicenna Biosciences is a drug development company using machine learning-enhanced medicinal chemistry to accelerate the lead-to-candidate…
Manifold Bio has built the first high-throughput in vivo (HTV) discovery engine—combining massively multiplexed in vivo screening and…
SIMPLIFYDRUGDISCOVERY. UNC at Chapel Hill – Machine Learning Via Web ApplicationBristol-Myers Squibb – Combinatorial Chemical Library…
To find the right drug for the right target…. Deep Apple Therapeutics is discovering new small-molecule therapeutics with unprecedented…
Overview
PharmEnable combines medicinal chemistry expertise with machine learning to find drug candidates for challenging protein targets. Founded in 2018 as a University of Cambridge spin-out, its Discovery Engine explores unusual chemical space that standard screening libraries miss. The company runs partnered programmes in neurology and oncology.
News
PharmEnable appoints Professor Jackie Hunter CBE as Corporate Advisor
We're delighted to welcome Professor Jackie Hunter CBE as Corporate Advisor to PharmEnable. Jackie's deep experience in pharma R&D, strategic partnerships and AI-driven innovation will be invaluable as PharmEnable advances its pipeline and collaborations.
Read more
Report
10 Cambridge AI spinouts
Meet 10 Cambridge spinouts, all hoping to harness the potential of AI for the good of the planet and its people.
Read more
Report
10 Cambridge spinouts changing the story of cancer
Meet 10 Cambridge spinouts, all putting their research into practice to improve patient outcomes.
Read more
Report
Clinical oncology pioneer joins PharmEnable's board
Exciting news at PharmEnable: we are proud to welcome Dr Ian Collins to our board as a new non-executive director. With three decades of experience in drug discovery and drug development, Ian will support our mission to push the boundaries of what is poss
Read more
Report
PharmEnable Therapeutics and Sosei Heptares Expand Drug Discovery Collaboration
PharmEnable Therapeutics and Sosei Heptares Expand Drug Discovery Collaboration The collaboration combines Sosei Heptares' leading structure-based drug design platform with PharmEnable's advanced artificial intelligence-enabled platform for designing high
Read more
Report
PharmEnable Closes $7.5M Financing led by MP Healthcare
PharmEnable Closes $7.5M Financing led by MP Healthcare to Develop Next Generation of Small Molecule Drugs to Treat Cancer and Neurological Diseases.
Read more
Report
Complex and structurally diverse: the next generation of small molecules
Small molecule drug discovery programmes often use commercial or proprietary compound libraries: a broad collection of molecules that are built by combining a wide variety of synthetically tractable building blocks. With such an extensive array of combina
Read more
Report
PharmEnable announces multi-target collaboration with Denali Therapeutics in neurodegenerative disease
The strategic collaboration aims to accelerate drug discovery in neurodegenerative disease Joint research programmes against multiple undisclosed targets to be initiated over the next two years PharmEnable to receive an upfront cash payment and potential
Read more
Report
PharmEnable awarded PLG Collaboration Deal of the Year Award
We are delighted that our business development team has been recognised with the prestigious Collaboration Deal of the Year Award by the Pharmaceutical Licensing Group for our shared-risk collaboration with Sosei Heptares, an international biopharmaceutic
Read more
Report
How an AI drug discovery collaboration between Nxera and PharmEnable is accelerating complex science: generating new hit molecules against a difficult GPCR target
Artificial Intelligence (AI) is becoming an increasingly important part of drug discovery - as demonstrated by the significant progress in the ongoing collaboration between Nxera and PharmEnable focused on a challenging peptidergic G protein-coupled recep
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Cambridge
United Kingdom
HQ
Financials
Total raised
$7.5M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2023 | $7.5M | Details |